— Know what they know.
Not Investment Advice

ALEC NASDAQ

Alector, Inc.
1W: -14.7% 1M: -0.5% 3M: +36.3% YTD: +39.9% 1Y: -24.6% 3Y: -59.3% 5Y: -92.3%
$2.14
+0.00 (+0.00%)
 
Weekly Expected Move ±13.5%
$2 $2 $2 $2 $3
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 50 · $237.6M mcap · 78M float · 1.24% daily turnover · Short 46% of daily vol
Smart Money Score
Moderate 50
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$237.6M
52W Range1.09-3.4
Volume4,699,039
Avg Volume966,265
Beta0.58
Dividend
Analyst Ratings
9 Buy 3 Hold 2 Sell
Consensus Buy
Company Info
CEOArnon Rosenthal
Employees103
SectorHealthcare
IndustryBiotechnology
IPO Date2019-02-07
131 Oyster Point Boulevard
South San Francisco, CA 94080
US
415 231 5660
About Alector, Inc.

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Recent Insider Trades

NameTypeSharesPriceDate
Wong-Sarad Grace S-Sale 3,625 $2.51 2026-09-04
Wong-Sarad Grace S-Sale 5,165 $2.67 2026-09-03
Berkley Neil Lindsay S-Sale 29,251 $2.66 2026-09-03
Rosenthal Arnon S-Sale 72,606 $2.66 2026-09-03
Wong-Sarad Grace S-Sale 656 $2.75 2026-09-02

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms